Stemming Pancreatic Cancer Before It Starts with KRAS Inhibitors
TL;DR
In a preclinical mouse study published in Science, researchers used KRAS inhibitors to eliminate precancerous pancreatic lesions (PanINs) before tumors formed, slowing cancer progression and nearly doubling or tripling survival compared with treating after cancer appeared. The work endorses the concept of cancer interception and sets the stage for clinical trials in high‑risk individuals, though PanINs are too small to detect with imaging and patient selection will be crucial for human application.
- Scientists Stop Pancreatic Cancer Before It Starts in Landmark Preclinical Study SciTechDaily
- An "Unexpected Finding" Into How Pancreatic Lesions Become Cancerous Technology Networks
- Pancreatic lesions show cancer traits but lack stromal support BioWorld News
- pancreatic precursor lesion (IMAGE) EurekAlert!
- Over 60% Of Healthy Adults Have Pancreatic Pre-Cancerous Lesions, Research Suggests StudyFinds
Want the full story? Read the original reporting
Read on SciTechDaily